BIOMEA FUSION INC. - COMMON STOCK

Biomea Fusion to Present New Preclinical Data on BMF-219 in Two Diabetic Animal Models at ADA 2022

01 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Biomea Fusion to Present New Preclinical Data Showing BMF-219’s Strong Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Tumor Models at ASCO 2022

26 May 2022 17:30:00 By Nasdaq GlobeNewswire

Biomea Fusion to Attend H.C. Wainwright Global Investment Conference

20 May 2022 12:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3

19 May 2022 07:00:00 By Nasdaq GlobeNewswire

Biomea Fusion Reports First Quarter 2022 Financial Results and Business Highlights

16 May 2022 06:30:00 By Nasdaq GlobeNewswire

Biomea Fusion to Participate in Bank of America Securities 2022 Healthcare Conference

09 May 2022 15:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces Acceptance of Multiple Abstracts at the 2022 ASCO Annual Meeting

27 Apr 2022 15:00:00 By Nasdaq GlobeNewswire

Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual Meeting

08 Apr 2022 12:00:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces Acceptance of Late Breaking Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022

06 Apr 2022 16:00:00 By Nasdaq GlobeNewswire

Biomea Fusion to Present at Oppenheimer’s 32nd Annual Virtual Healthcare Conference

15 Mar 2022 07:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces Upcoming Presentations of Preclinical Data in Diffuse Large B-Cell Lymphoma, Multiple Myeloma, and Several KRAS Mutant Solid Tumors for BMF-219 at AACR Annual Meeting 2022

08 Mar 2022 17:15:00 By Nasdaq GlobeNewswire

Biomea Fusion Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

28 Feb 2022 15:05:01 By Nasdaq GlobeNewswire

Biomea Fusion Announces Appointment of Steve Morris, M.D. as Chief Medical Officer

01 Feb 2022 05:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces First Patient Dosed

25 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces Participation at the H.C. Wainwright 2022 BioConnect Conference

11 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces 2022 Clinical Development Plan to Initiate Studies in up to Seven Different Tumor Types and in Diabetes for BMF-219

10 Jan 2022 07:30:01 By Nasdaq GlobeNewswire

Biomea Fusion Releases Pre-Clinical Data with BMF-219 in Diabetes

06 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Moves into New Headquarters and Expands R&D Facility

04 Jan 2022 12:30:14 By Nasdaq GlobeNewswire

Biomea Fusion to Present at the 40th Annual J.P. Morgan Healthcare Conference

21 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Biomea Fusion to be added to NASDAQ Biotechnology Index

14 Dec 2021 07:00:01 By Nasdaq GlobeNewswire